SPIRIVA RESPIMAT Drug Patent Profile

Which patents cover Spiriva Respimat, and when can generic versions of Spiriva Respimat launch?

Spiriva Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has eighty patent family members in thirty-five countries.

The generic ingredient in SPIRIVA RESPIMAT is tiotropium bromide. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the tiotropium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Spiriva Respimat

A generic version of SPIRIVA RESPIMAT was approved as tiotropium bromide by LUPIN on June 20^th, 2023.

Summary for SPIRIVA RESPIMAT

International Patents:	80
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	27
Patent Applications:	3,917
Drug Prices:	Drug price information for SPIRIVA RESPIMAT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SPIRIVA RESPIMAT
What excipients (inactive ingredients) are in SPIRIVA RESPIMAT?	SPIRIVA RESPIMAT excipients list
DailyMed Link:	SPIRIVA RESPIMAT at DailyMed

See drug prices for SPIRIVA RESPIMAT

Recent Clinical Trials for SPIRIVA RESPIMAT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Saskatchewan	Phase 4
Nemours Children's Clinic	Phase 2
Rho, Inc.	Phase 2

See all SPIRIVA RESPIMAT clinical trials

Pharmacology for SPIRIVA RESPIMAT

Drug Class	Anticholinergic
Mechanism of Action	Cholinergic Antagonists

Paragraph IV (Patent) Challenges for SPIRIVA RESPIMAT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SPIRIVA RESPIMAT	Inhalation Aerosol	tiotropium bromide	2.5 mcg per actuation	021936	1	2023-03-07

US Patents and Regulatory Information for SPIRIVA RESPIMAT

SPIRIVA RESPIMAT is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015		RX	Yes	Yes	7,284,474*PED				Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes	7,396,341*PED				Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes	7,284,474*PED				Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes	7,837,235*PED				Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes	8,733,341*PED				Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes	9,027,967*PED				Y

Expired US Patents for SPIRIVA RESPIMAT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014	6,988,496*PED
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015	7,246,615
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014	6,149,054*PED
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014	6,846,413*PED
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014	7,104,470*PED
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015	7,988,001*PED
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015	6,726,124*PED

International Patents for SPIRIVA RESPIMAT

See the table below for patents covering SPIRIVA RESPIMAT around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	0664733
Brazil	0008423	cartucho para um lìquido, bem como dispositivo de distribuição compreendendo o mesmo.
Peru	29098	DISPOSITIVO PARA LA GENERACION DE ALTA PRESION EN UN FLUIDO EN REALIZACION MINIATURA, PULVERIZADOR CON DICHO DISPOSITIVO Y SU EMPLEO
Germany	69333938
Norway	981521
Japan	4317664
Germany	19742439	Mikrostrukturiertes Filter (Fluid micro-filter)

Supplementary Protection Certificates for SPIRIVA RESPIMAT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0418716	SPC/GB02/036	United Kingdom		PRODUCT NAME: SCOPINE DI-(2-THIENYL)GLYCOLATE IN THE FORM OF THE QUATERNARY SALTS - ESPECIALLY SALTS OF TIOTROPIUM - PREFERRED TIOTROPIUMBROMIDE AND TIOTROPIUMBROMIDE MONOHYDRATE; REGISTERED: NL RVG26191 20011009; UK PL14598/0062 20020514
0418716	C300084	Netherlands		PRODUCT NAME: ZOUTEN VAN TRIOTROPIUM, IN HET BIJZONDER TIOTROPIUM BROMIDE; REGISTRATION NO/DATE: RVG 26191 20011009
0418716	300084	Netherlands		PRODUCT NAME: ZOUTEN VAN TRIOTROPIUM, IN HET BIJZONDER TIOTROPIUM BROMIDE; REGISTRATION NO/DATE: RVG 26191 20011009
0418716	05C0039	France		PRODUCT NAME: TIOTROPIUM MONOHYDRATE DE BROMURE; NAT. REGISTRATION NO/DATE: NL 31393 20050708; FIRST REGISTRATION: RVG 26191 20011009
0418716	0290010-8	Sweden		PRODUCT NAME: TIOTROPIUM, 3BETA-(DI(2-TIENYL)HYDROXIACETOXI)-6BETA,7BETA-EPO XI-8METYL-1ALFAH,5ALFAH-TROPANIUM, ELLER ETT SALT DAERAV; NAT. REGISRTATION NO/DATE: 18094 20020503; FIRST REGISTRATION: NL RVG 26 191 20011009

Market Dynamics and Financial Trajectory for SPIRIVA RESPIMAT

Last updated: September 24, 2025

---

Introduction

SPIRIVA RESPIMAT (tiotropium bromide inhalation powder) stands as a cornerstone in the management of chronic obstructive pulmonary disease (COPD) and asthma. Since its debut, it has established a dominant market position, driven by innovative delivery technology, clinical efficacy, and robust pharmacoeconomic profiles. This analysis explores the evolving market landscape, competitive dynamics, revenue trajectory, and future growth prospects for SPIRIVA RESPIMAT, underpinned by recent regulatory, clinical, and commercial developments.

---

Market Overview

COPD and Asthma: Global Burden and Treatment Landscape

COPD affects over 250 million people globally, making it among the leading causes of morbidity and mortality, with substantial economic impact[1]. Asthma further complicates respiratory disease management, affecting approximately 300 million individuals worldwide[2]. Effective inhalation therapies, particularly long-acting bronchodilators like tiotropium, are central to maintenance treatment. The global respiratory drug market exceeds USD 35 billion, with inhaled corticosteroids and long-acting muscarinic antagonists (LAMAs) like SPIRIVA constituting key segments[3].

SPIRIVA RESPIMAT's Position in the Market

Since its FDA approval in 2004, SPIRIVA RESPIMAT has maintained a leading position, particularly within LAMA categories. Its unique inhaler technology, the Respimat Soft Mist inhaler, offers improved lung deposition, ease of use, and patient preference advantages. As of 2022, SPIRIVA commanded approximately 40% market share in the global LAMA segment[4].

---

Market Dynamics

1. Competitive Environment

The respiratory market is intensely competitive, with key rivals including glycopyrrolate, aclidinium, umeclidinium, and combination therapies. Notably:

• Generic Entry: The expiration of patents for some formulations poses revenue threats, though Tiotropium's long patent life for specific formulations enables continued exclusivity.
• Combination Therapies: The advent of fixed-dose combinations (e.g., SPIRIVA + INDACATEROL) enhances patient adherence but also introduces competition.
• Emerging Therapies: Biologics and innovative drug delivery platforms might influence future positioning but currently target different subpopulations.

2. Technological and Formulation Innovations

SPIRIVA RESPIMAT leverages the Respimat inhaler technology, which has gained regulatory approvals for additional indications, including asthma. The device’s superior aerosol characteristics have catalyzed its adherence and persistence rates, boosting market adoption[5].

3. Regulatory Landscape

Regulatory bodies have supported SPIRIVA RESPIMAT’s sustained use with a series of approvals, including extended indications and approval of combination formulations. The FDA’s 2018 approval of SPIRIVA RESPIMAT as a maintenance treatment for asthma marked a notable expansion.

4. Patient and Prescriber Preferences

Ease of use, reduced inhalation errors, and demonstrable clinical benefits position SPIRIVA favorably among prescribers and patients. Despite competition, its reputation for reliability sustains demand.

---

Financial Trajectory

1. Revenue Trends and Forecasts

• Historical Performance: From its launch through 2021, SPIRIVA accumulated peak global annual revenues exceeding USD 4 billion[6].

• 2022-2025 Outlook: Growth is projected to stabilize but remain resilient due to:

  • Expanding indications (e.g., asthma in select markets).
  • Growing COPD prevalence, especially in Asia-Pacific regions.
  • Continued device improvements and patient adherence programs.

• Impact of Generic Competition: Patent cliffs in certain jurisdictions (e.g., Europe in late 2010s) led to revenue erosion, but the flagship formulations maintained market share through brand loyalty and device differentiation.

2. Partner Contributions and Market Penetration

Boehringer Ingelheim's partnership with GlaxoSmithKline (GSK) for SPIRIVA has enabled extensive global reach. GSK's extensive sales force and marketing strategies have reinforced SPIRIVA’s market presence, particularly in emerging markets.

3. Pricing and Reimbursement Dynamics

Pricing remains a critical component, with reimbursement policies varying widely across markets. Favorable reimbursement, especially for COPD management, sustains revenue streams. Increased formulary inclusion and health technology assessments (HTAs) have generally supported price stability[7].

---

Future Growth Drivers

1. Geographic Expansion

• Emerging Markets: Asia-Pacific regions, notably China and India, show accelerating COPD prevalence and increasing adoption of inhaled therapies.
• Regulatory Approvals: Efforts to secure approvals for new indications and formulations in untapped markets can generate additional revenues.

2. Indication Expansion and Line Extensions

• Asthma: GSK’s approval for asthma expands the drug’s addressable patient pool.
• Combination Devices: Development of dual therapy inhalers combining tiotropium with inhaled corticosteroids or long-acting beta-agonists may enhance adherence and improve outcomes.

3. Technological Advancements

• Smart Inhalers: Integrating digital health solutions with Respimat devices could improve adherence, monitor compliance, and generate data-driven insights for personalized therapy.

4. Competitive Differentiation

• Maintaining technological superiority and maximizing patient-centric benefits will be key to defending market share. Continued investment in device innovation and clinical research will underpin this strategy.

---

Risks and Challenges

• Patent Expirations: Potential patent expiry could invite generic competition, pressuring pricing and revenues.
• Regulatory Hurdles: Delays or restrictions related to new indications or formulations may impede growth.
• Market Saturation: Maturity in primary markets might limit revenue growth unless supplemented by expansion strategies.
• Pricing Pressures: Increasing emphasis on cost-effectiveness assessments could restrict pricing flexibility.

---

Conclusion

Market Dynamics Summary

SPIRIVA RESPIMAT remains a pivotal asset within respiratory therapeutics, supported by technological sustainability, clinical value, and strategic market expansion. While upcoming patent expiries and generic competition pose challenges, continued innovation, geographic penetration, and indication broadening bolster its market resilience.

Financial Trajectory Outlook

Steady revenues over the next few years are anticipated, supplemented by growth in emerging markets and with potential upticks due to advanced formulations and digital health integration. Long-term sustainability hinges on proactive adaptation to competitive pressures and regulatory landscapes.

---

Key Takeaways

• Market Leadership: SPIRIVA RESPIMAT’s technological edge and clinical reliability sustain its leadership in the COPD/LAMA segments.
• Emerging Market Potential: Significant growth opportunities exist in Asia-Pacific, driven by rising disease burden and increasing healthcare access.
• Innovation Focus: Device improvements and digital health integration are vital to maintaining competitive differentiation.
• Regulatory and Patent Strategies: Vigilant management of patent lifecycles and regulatory pathways is essential to preserve revenue streams.
• Strategic Diversification: Expanding indications and combination therapies can mitigate risks associated with patent expiry and market saturation.

---

FAQs

1. How is SPIRIVA RESPIMAT positioned amid upcoming generic competitors?
While patent expiries threaten formulations without patent protection, ongoing innovation, device differentiation, and entrenched prescriber/nurse preferences help sustain its market share, especially for formulations with patent exclusivity.

2. What role does digital health play in SPIRIVA RESPIMAT’s future growth?
Integrating digital inhaler technologies can enhance adherence, provide valuable usage data, and differentiate the product, ultimately reinforcing its market position in an increasingly data-driven healthcare environment.

3. Which emerging markets offer the most growth potential for SPIRIVA RESPIMAT?
Asia-Pacific countries, including China, India, and Southeast Asian nations, present substantial opportunities due to rising COPD prevalence, expanding healthcare infrastructure, and increased adoption of inhaled therapies.

4. How might combination therapies impact SPIRIVA RESPIMAT’s market share?
Fixed-dose combinations can improve adherence and clinical outcomes, positioning SPIRIVA RESPIMAT alongside competitors offering similar formulations, thereby expanding its therapeutic scope.

5. What are the primary risks to SPIRIVA RESPIMAT’s long-term financial performance?
Patent expiration without effective repositioning, regulatory delays, market saturation, and pricing pressures pose significant risks, emphasizing the need for ongoing innovation and strategic market development.

---

References

[1] World Health Organization. "Global surveillance, prevention and control of chronic respiratory diseases." 2017.
[2] Global Initiative for Asthma. "GINA Report, Global Strategy for Asthma Management and Prevention." 2022.
[3] MarketWatch. "Respiratory drugs market size, share, growth." 2022.
[4] IQVIA. "IQVIA MIDAS Data, 2022."
[5] GSK. "SPIRIVA RESPIMAT product information." 2022.
[6] Statista. "Pharmaceutical sales of SPIRIVA worldwide." 2022.
[7] IQVIA. "Pricing and reimbursement landscape for respiratory therapies." 2022.